Business Wire

New Era of Remote Working Calls for Modern Security Mindset, Finds Thales Global Survey of IT Leaders

14.9.2021 10:00:00 EEST | Business Wire | Press release

Share

COVID-19 quickly ushered in the era of remote work, introducing new risks that IT professionals are struggling to manage with existing security tools, according to a new Thales study. Six in 10 respondents said traditional security tools such as VPNs are still the primary vehicle for employees accessing applications remotely -- likely the reason why almost half (44%) were not confident that their access security systems could scale effectively to secure remote work.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005014/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

These are among the key insights from the 2021 Thales Access Management Index, a global survey of 2,600 IT decision makers, commissioned by Thales and conducted by 451 Research, part of S&P Global Market Intelligence, to better understand the new security risks and challenges caused by the rise of remote working and cloud transformation caused by the COVID-19 pandemic.

Last year saw a surge in cybercrime exploiting the various aspects of the COVID-19 pandemic and the shift to remote work, with ransomware attacks soaring by 150%.1 The Thales survey found the pandemic’s effects have had a significant impact on security infrastructure, particularly on access management and authentication frameworks, pushing organisations to adopt modern security strategies like Zero Trust to support the demands of a more mobile and remote workforce.

Era of Remote Working – Concerns Catalyse Change

According to the index, respondents have many different systems deployed for remote access. When asked about the technologies that were in place, VPN was the most common, with 60% of IT professionals identifying the capability. Virtual Desktop Infrastructure, cloud-based access and Zero Trust network access/software defined perimeter (ZTNA/SDP) closely followed. However, when asked what new access technologies respondents were planning to deploy due to the pandemic, nearly half (44%) indicated ZTNA/SDP was the top technology choice.

Thales also explored respondents’ plans to move beyond traditional VPN environments, and found that nearly 40% expect to replace their VPN with ZTNA/SDP, while 38% expect to move to a Multi-Factor Authentication (MFA) solution. This confirms the need for more modern, sophisticated authentication capabilities is driving change in many organisations and is perceived as a key enabler of Zero Trust security.

“Seemingly overnight, remote access went from being an exception to the default working model for a large swath of employees. As a result, businesses are navigating a volatile and complex world, and adopting a Zero Trust model of cybersecurity will enable them to continue to conduct operations safely amidst the uncertainty,” said Francois Lasnier, vice president of Access Management solutions at Thales. “One of the core barrier businesses face when starting their Zero Trust journey is the balance between locking down access without interrupting workflow. People require access to sensitive data in order to work and collaborate and businesses leaders will need to ensure that a drop in productivity doesn’t become an unwanted side effect. The research shows that IT professionals increasingly see access management and modern authentication capabilities as key component in achieving a Zero Trust model.”

Room to Grow with Zero Trust

The Thales report found that Zero Trust models are the solution of choice for respondents seeking to improve access environments, yet many are still in the early stage of adoption.

According to the research, less than a third (30%) of the respondents claim to have a formal strategy and have actively embraced a Zero Trust policy. Additionally, almost half (45%) are either planning, researching or considering a Zero Trust strategy. Surprisingly, less than a third (32%) of the respondents indicated that Zero Trust shapes their cloud security strategy to a great extent.

Access Security Needs to Adapt to Deal with Dynamic Workplaces

A silver lining of the pandemic-driven rush to remote working is the acceleration of improved approaches to access security. Thales found that 55% of respondents currently have adopted two-factor authentication within their organisations. Regionally, there was notable variation, with the UK leading (64%), followed by the U.S. (62%), APAC (52%) and LATAM (40%). These varying degrees of adoption may be due to the level at which better access management is prioritised in security investments.

Yet, despite the well-known limitations of passwords, investment in MFA still trails other security tools like firewalls, endpoint security, SIEM and email security. Remote access users are still the main use case for MFA adoption (71%). One-third of respondents that have adopted MFA use more than three different authentication tools, signaling the need for a more unified approach to access management in the future.

“Security tools and approaches need to adapt to better support the era of remote working,” said Eric Hanselman, chief analyst at 451 Research, part of S&P Global Market Intelligence. “The shift towards a Zero Trust model, along with increasing use of modern authentication technologies, like adaptive and multifactor authentication (MFA), will improve organisations’ security posture. This will be an exciting space to watch as businesses continue to deal with dynamic workplace environments.” 2

Thales and 451 Research will discuss the global findings in more detail during its upcoming Trusted Access Summit on 5 October 2021. To join, please visit the registration page.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.

PLEASE VISIT

Thales Group
Security

1 Group-IB Ransomware Uncovered 2020-2021
2 Quote from Thales 2021 Global Access Management Index

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT

Thales, Media Relations
Security

Constance Arnoux
+33 (0)6 44 12 16 35
Constance.arnoux@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye